Transcriptomic characterization of the histopathological growth patterns in breast cancer liver metastases.

Histopathological growth pattern Liver metastasis Metastatic breast cancer Transcriptomics

Journal

Clinical & experimental metastasis
ISSN: 1573-7276
Titre abrégé: Clin Exp Metastasis
Pays: Netherlands
ID NLM: 8409970

Informations de publication

Date de publication:
29 Mar 2024
Historique:
received: 05 12 2023
accepted: 06 02 2024
medline: 29 3 2024
pubmed: 29 3 2024
entrez: 29 3 2024
Statut: aheadofprint

Résumé

Metastatic breast cancer (mBC) remains incurable and liver metastases (LM) are observed in approximately 50% of all patients with mBC. In some cases, surgical resection of breast cancer liver metastases (BCLM) is associated with prolonged survival. However, there are currently no validated marker to identify these patients. The interactions between the metastatic cancer cells and the liver microenvironment result in two main histopathological growth patterns (HGP): replacement (r-HGP), characterized by a direct contact between the cancer cells and the hepatocytes, and desmoplastic (d-HGP), in which a fibrous rim surrounds the tumor cells. In patients who underwent resection of BCLM, the r-HGP is associated with a worse postoperative prognosis than the d-HGP. Here, we aim at unraveling the biological differences between these HGP within ten patients presenting both HGP within the same metastasis. The transcriptomic analyses reveal overexpression of genes involved in cell cycle, DNA repair, vessel co-option and cell motility in r-HGP while angiogenesis, wound healing, and several immune processes were found overexpressed in d-HGP LM. Understanding the biology of the LM could open avenues to refine treatment of BC patients with LM.

Identifiants

DOI: 10.1007/s10585-024-10279-1 PMID: 38548918
pubmed: 38548918
doi: 10.1007/s10585-024-10279-1
pii: 10.1007/s10585-024-10279-1
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Fondation contre le Cancer
ID : C/2020/1441

Informations de copyright

© 2024. The Author(s).

Références

Harbeck N, Penault-Llorca F, Cortes J et al (2019) Breast cancer. Nat Rev Dis Primers. https://doi.org/10.1038/S41572-019-0111-2 . 5:
doi: 10.1038/S41572-019-0111-2 pubmed: 31548545
Adam R, Aloia T, Krissat J et al (2006) Is liver resection justified for patients with hepatic metastases from breast Cancer? Ann Surg 244:897. https://doi.org/10.1097/01.SLA.0000246847.02058.1B
doi: 10.1097/01.SLA.0000246847.02058.1B pubmed: 17122615 pmcid: 1856635
Bale R, Putzer D, Schullian P (2019) Local treatment of breast Cancer Liver Metastasis. Cancers (Basel) 11:1341. https://doi.org/10.3390/cancers11091341
doi: 10.3390/cancers11091341 pubmed: 31514362
Pivot X, Asmar L, Hortobagyi GN et al (2000) A retrospective study of first indicators of breast Cancer recurrence. Oncology 58:185–190. https://doi.org/10.1159/000012098
doi: 10.1159/000012098 pubmed: 10765118
Leung AM, Vu HN, Nguyen KA et al (2010) Effects of Surgical Excision on Survival of patients with stage IV breast Cancer. J Surg Res 161:83–88. https://doi.org/10.1016/J.JSS.2008.12.030
doi: 10.1016/J.JSS.2008.12.030 pubmed: 19375721
Cristofanilli M, Hortobagyi GN (2001) New Horizons in treating metastatic disease. Clin Breast Cancer 1:276–287. https://doi.org/10.3816/CBC.2001.N.002
doi: 10.3816/CBC.2001.N.002 pubmed: 11899350
Eng LG, Dawood S, Sopik V et al (2016) Ten-year survival in women with primary stage IV breast cancer. Breast Cancer Res Treat 160:145–152. https://doi.org/10.1007/S10549-016-3974-X/FIGURES/2
doi: 10.1007/S10549-016-3974-X/FIGURES/2 pubmed: 27628191
Leduc S, De Schepper M, Vermeulen P et al (2023) Histopathological growth patterns and tumor infiltrating lymphocytes in breast cancer liver metastases. NPJ Breast Cancer Press 83. https://doi.org/10.1158/1538-7445.SABCS22-P6-14-06 . P6-14-06
Bohlok A, Vermeulen P, Leduc S et al (2020) Association between the histopathological growth patterns of liver metastases and survival after hepatic surgery in breast cancer patients. NPJ Breast Cancer 6:64. https://doi.org/10.1038/s41523-020-00209-1
doi: 10.1038/s41523-020-00209-1 pubmed: 33339824 pmcid: 7749172
Latacz E, Höppener D, Bohlok A et al (2022) Histopathological growth patterns of liver metastasis: updated consensus guidelines for pattern scoring, perspectives and recent mechanistic insights. Br J Cancer 2022 127(6):988–1013. https://doi.org/10.1038/s41416-022-01859-7
doi: 10.1038/s41416-022-01859-7
Fernández Moro C, Geyer N, Harrizi S et al (2023) An idiosyncratic zonated stroma encapsulates desmoplastic liver metastases and originates from injured liver. Nat Commun 14:5024. https://doi.org/10.1038/s41467-023-40688-x
doi: 10.1038/s41467-023-40688-x pubmed: 37596278 pmcid: 10439160
Van Dam PJ, Van Der Stok EP, Teuwen LA et al (2017) International consensus guidelines for scoring the histopathological growth patterns of liver metastasis. Br J Cancer 117:1427–1441. https://doi.org/10.1038/BJC.2017.334
doi: 10.1038/BJC.2017.334 pubmed: 28982110 pmcid: 5680474
Qiagen (2018) miRNeasy FFPE Handbook
Aran D, Hu Z, Butte AJ (2017) xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol 18:1–14. https://doi.org/10.1186/S13059-017-1349-1/FIGURES/4
doi: 10.1186/S13059-017-1349-1/FIGURES/4
Bosi C, Bartha Á, Galbardi B et al (2023) Pan-cancer analysis of antibody-drug conjugate targets and putative predictors of treatment response. Eur J Cancer 195:113379. https://doi.org/10.1016/j.ejca.2023.113379
doi: 10.1016/j.ejca.2023.113379 pubmed: 37913680
Dong BC, Luo X, Qi C et al (2023) Targeting pioneer transcription factor Ascl1 to promote optic nerve regeneration. https://doi.org/10.1101/2023.07.20.549959 . BioRxive
García-Gómez P Valiente · Manuel (123AD) vascular co-option in brain metastasis. Angiogenesis 23:3–8. https://doi.org/10.1007/s10456-019-09693-x
Frentzas S, Simoneau E, Bridgeman VL et al (2016) Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases. Nat Med 22:1294–1302. https://doi.org/10.1038/nm.4197
doi: 10.1038/nm.4197 pubmed: 27748747 pmcid: 5104270
Lingg L, Rottenberg S, Francica P (2022) Meiotic genes and DNA double strand break repair in Cancer. Front Genet 13. https://doi.org/10.3389/FGENE.2022.831620
Hu M, Chen Z, Hu D et al (2022) Delineating the molecular landscape of different histopathological growth patterns in colorectal cancer liver metastases. Front Immunol 13:1045329. https://doi.org/10.3389/FIMMU.2022.1045329/FULL
Stremitzer S, Vermeulen P, Graver S et al (2020) Immune phenotype and histopathological growth pattern in patients with colorectal liver metastases. Br J Cancer 122:1518–1524. https://doi.org/10.1038/s41416-020-0812-z
Liang J-Y, Xi S-Y, Shao Q et al (2020) Histopathological growth patterns correlate with the immunoscore in colorectal cancer liver metastasis patients after hepatectomy. 69:2623–2634. https://doi.org/10.1007/s00262-020-02632-6
Höppener DJ, Nierop PMH, Hof J et al (2020) Enrichment of the tumour immune microenvironment in patients with desmoplastic colorectal liver metastasis. Br J Cancer 123:196–206. https://doi.org/10.1038/s41416-020-0881-z
doi: 10.1038/s41416-020-0881-z pubmed: 32418992 pmcid: 7374625
Cheng J, Wei J, Tong T et al (2019) Prediction of histopathologic growth patterns of Colorectal Liver metastases with a noninvasive imaging method. Ann Surg Oncol 26(13):4587–4598. https://doi.org/10.1245/s10434-019-07910-x
doi: 10.1245/s10434-019-07910-x pubmed: 31605342
Starmans MPA, Buisman FE, Renckens M et al (2021) Distinguishing pure histopathological growth patterns of colorectal liver metastases on CT using deep learning and radiomics: a pilot study. Clin Exp Metastasis 38(5):483–494. https://doi.org/10.1007/s10585-021-10119-6
doi: 10.1007/s10585-021-10119-6 pubmed: 34533669 pmcid: 8510954

Auteurs

Sophia Leduc (S)

Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Herestraat 49, box 810, Leuven, 3000, Belgium.

Ha-Linh Nguyen (HL)

Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Herestraat 49, box 810, Leuven, 3000, Belgium.

François Richard (F)

Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Herestraat 49, box 810, Leuven, 3000, Belgium.

Gitte Zels (G)

Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Herestraat 49, box 810, Leuven, 3000, Belgium.

Amena Mahdami (A)

Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Herestraat 49, box 810, Leuven, 3000, Belgium.

Maxim De Schepper (M)

Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Herestraat 49, box 810, Leuven, 3000, Belgium.
Department of Pathology, University Hospitals Leuven, Leuven, Belgium.

Marion Maetens (M)

Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Herestraat 49, box 810, Leuven, 3000, Belgium.

Anirudh Pabba (A)

Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Herestraat 49, box 810, Leuven, 3000, Belgium.

Joris Jaekers (J)

Department of Visceral Surgery, University Hospitals Leuven, KU Leuven, Leuven, Belgium.

Emily Latacz (E)

Translational Cancer Research Unit, GZA Hospitals Antwerp, Antwerp, Belgium.

Ali Bohlok (A)

Department of Surgical Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.

Evy Vanderheyden (E)

Laboratory of Translational Genetics, VIB-KU Leuven, Leuven, Belgium.

Thomas Van Brussel (T)

Laboratory of Translational Genetics, VIB-KU Leuven, Leuven, Belgium.

Bram Boeckx (B)

Laboratory of Translational Genetics, VIB-KU Leuven, Leuven, Belgium.

Rogier Schepers (R)

Laboratory of Translational Genetics, VIB-KU Leuven, Leuven, Belgium.

Diether Lambrechts (D)

Laboratory of Translational Genetics, VIB-KU Leuven, Leuven, Belgium.

Luc Dirix (L)

Translational Cancer Research Unit, GZA Hospitals Antwerp, Antwerp, Belgium.

Denis Larsimont (D)

Department of Anatomopathology, Institut Jules Bordet, Brussels, Belgium.

Sophie Vankerckhove (S)

Department of Surgical Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.

Valerio Lucidi (V)

Department of Abdominal Surgery, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium.

Baki Topal (B)

Department of Visceral Surgery, University Hospitals Leuven, KU Leuven, Leuven, Belgium.

Imane Bachir (I)

Department of Anesthesiology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.

Vincent Donckier (V)

Department of Surgical Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.

Giuseppe Floris (G)

Department of Pathology, University Hospitals Leuven, Leuven, Belgium.
Department of Imaging and Pathology, Laboratory of Translational Cell & Tissue Research and University Hospitals Leuven, KU Leuven, Leuven, Belgium.

Peter Vermeulen (P)

Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Herestraat 49, box 810, Leuven, 3000, Belgium.
Translational Cancer Research Unit, GZA Hospitals Antwerp, Antwerp, Belgium.

Christine Desmedt (C)

Laboratory for Translational Breast Cancer Research, Department of Oncology, KU Leuven, Herestraat 49, box 810, Leuven, 3000, Belgium. Christine.desmedt@kuleuven.be.

Classifications MeSH